Masters is actively seeking the acquisition, distribution or licensing in of late-stage and commercialised specialty pharmaceuticals and devices. We are interested in obtaining the global rights to products to complement our current portfolio, particularly in the following areas:
- Rare, orphan diseases
- Hospital care
- Infectious diseases
The acquisitions of product portfolios or organisations that complement and add value to our operations is another key strand of Masters' strategy.
Our experience of successfully meeting different regulatory requirements, particularly in emerging markets, ensures that we will increase global demand for new and established products.